Osteoporosis in men.
Osteoporosis is defined as "a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture". Approximately 40-50% of women sustain osteoporotic fractures in their lifetime; as such, it is appropriate that studies initially focused upon females. Despite an increased recognition of osteoporotic fractures in men, there continues to be neglect of this disease in males. This ongoing neglect is inappropriate as 25-33% of men in some populations will sustain osteoporotic fractures in their lifetime. Testosterone plays an important role in male skeletal health. However, recent data suggest that estrogen may in fact be the dominant hormone regulating skeletal status in both men and women. BMD measurement may be utilized for osteoporosis diagnosis and to assist with fracture risk prediction in men prior to their sustaining a fracture. Recognizing this need, the International Society for Clinical Densitometry (ISCD) recommended and recently reaffirmed use of a BMD T-score of -2.5 or below be utilized to diagnose osteoporosis in men. Androgen therapy of hypogonadal men may be considered with the caveat that data do not exist to document that this treatment reduces fracture risk. At this time, the data is inadequate to support use of androgen treatment in eugonadal men with osteoporosis. Parathyroid hormone treatment does increase BMD; existing studies have not been of adequate size or duration to document fracture reduction efficacy. Bisphosphonate therapy increases BMD, reduces vertebral fracture risk and is considered the standard of care for osteoporotic men at this point in time.
Binkley
Neil
N
Osteoporosis Clinical Center and Research Program, Institute on Aging, University of Wisconsin, Madison, WI 53705, USA. nbinkley@wisc.edu
D000728:Androgens / Q000627:therapeutic use; D015519:Bone Density; D003720:Densitometry; D004967:Estrogens / Q000627:therapeutic use; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D008297:Male; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D012307:Risk Factors; D012737:Sex Factors; D013739:Testosterone / Q000627:therapeutic use
D000728:Androgens; D004967:Estrogens; D013739:Testosterone